A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
NCT ID: NCT06724848
Last Updated: 2026-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
850 participants
OBSERVATIONAL
2024-06-05
2027-10-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Value of Inflammatory Biomarkers and FEV1 for COPD
NCT03532893
Heterogeneity and Development of Early COPD
NCT06096285
Perception of Symptom Variability in COPD
NCT01753427
Realize the Current Situation of COPD Patients in China
NCT03131362
Small Bioactive Molecules in Early COPD Diseases
NCT04950023
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
Healthy controls from asthma translational study: at least 50 healthy participants aged 30 or older.
No interventions assigned to this group
Cohort B
early COPD, normal lung function with symptoms approximately 200 smokers or ex-smokers, early COPD participants at 30 to 45 years of age (inclusive) with normal lung function defined as FEV1/FVC ratio \> 70% (lower limit of normal) and FEV1 \> 80% of predicted normal with symptoms defined as presence of chronic cough and/or chronic sputum and/or breathlessness equivalent to mMRC Grade 1 or higher, with any of the risk factors below:
* History suggestive of COPD exacerbation;
* Evidence of emphysema on CT scan;
* Evidence of small airways disease on CT scan or oscillometry.
No interventions assigned to this group
Cohort C1
Approximately 100 physician diagnosed COPD participants with mild airflow limitation defined as post-bronchodilation FEV1/FVC \< 70% and FEV1 ≥ 80% of predicted. Participants at 30 to 50 years of age (inclusive)
No interventions assigned to this group
Cohort C2
Approximately 100 physician diagnosed COPD participants with mild airflow limitation defined as post-bronchodilation FEV1/FVC \< 70% and FEV1 ≥ 80% of predicted. Defined as participants elder than 50 years of age (exclusive)
No interventions assigned to this group
Corhort D
Moderate to very severe COPD Approximately 450 COPD participants (males and females aged 50 years or older) with moderate to very severe airflow limitation defined as post-bronchodilation FEV1/FVC \< 70% and FEV1 ≥ 25% and \<80% of predicted, and presence of respiratory symptoms quivalent to CAT ≥ 10 or mMRC ≥ 2.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to perform acceptable lung function testing for FEV1 according to American Thoracic Society and European Respiratory Society 2019 acceptability criteria.
* Able and willing to comply with the requirements of the protocol including ability to read, write, be fluent in the translated language of all participants facing questionnaires used at center.
* Participants will be allowed to enroll into other studies while taking part in this study. However, permission from the Steering Committee must be obtained to enroll or allow the continued participation of a participant enrolled in another study.
Exclusion Criteria
* The participant has an altered mental status at the time of informed consent.
* Clinically significant abnormal laboratory values available vital signs, ECG, or laboratory testing at the screening assessment that, which in the opinion of the investigator, could interfere with the objectives of the study or safety of the participant.
* Current diagnosis of asthma according to the Global Initiative for Asthma or other accepted guidelines, prior history of asthma, or asthma-COPD overlap. Childhood history of asthma is allowed and defined as asthma diagnosed and resolved (ie, not requiring the use of any maintenance or rescue medication) before the age of 18.
* Clinically important pulmonary disease (as discretion by local physician) other than COPD (eg, active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, hypoventilation syndrome associated with obesity, lung cancer, alpha-1 anti-trypsin deficiency, and primary ciliary dyskinesia).
* COPD exacerbation, within 2 weeks prior to enrollment, that was treated with systemic corticosteroids and/or antibiotics, and/or led to hospitalization (based on last dose of corticosteroids or antibiotics, or last date of hospitalization, whichever occurred later).
* History of partial or total lung resection (single lobe or segmentectomy is acceptable). Surgical or endoscopic (eg, valves) lung volume reduction within the 6 months prior to enrollment. Expected need for lung volume reduction surgery during the study.
* Unstable disorders, including, but not limited to, autoimmune disease, diabetes, thyroid disease, significant cardio-renal disease (including significant hypertension, atrial fibrillation, hypertrophic cardiomyopathy, and significant cardiovascular disease).
* Malignancy, current or within the past 5 years, except for adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma-in-situ treated with apparent success more than one year prior to enrollment. Suspected malignancy or undefined neoplasms.
* Terminal disease and/or organ failure or participants otherwise considered not appropriate for the study participation.
* Participants receipt investigational biologics within 3 months or 5 half-lives prior to visit 1, whichever is longer.
* Participants who are actively enrolled in an interventional clinical trial.
* Female participants who are pregnant.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, , China
Research Site
Changsha, , China
Research Site
Chengdu, , China
Research Site
Guangzhou, , China
Research Site
Hefei, , China
Research Site
Nanjing, , China
Research Site
Nanning, , China
Research Site
Shanghai, , China
Research Site
Shenyang, , China
Research Site
Wuhan, , China
Research Site
Xuzhou, , China
Research Site
Zhengzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D2287R00187
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.